Affinity DataKi: 2.50E+3nMAssay Description:Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysisMore data for this Ligand-Target Pair
Affinity DataKi: 7.50E+3nMAssay Description:Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysisMore data for this Ligand-Target Pair
Affinity DataKi: 8.60E+3nMAssay Description:Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysisMore data for this Ligand-Target Pair
Affinity DataKi: 1.22E+4nMAssay Description:Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysisMore data for this Ligand-Target Pair
Affinity DataKi: 2.41E+4nMAssay Description:Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysisMore data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetD-3-phosphoglycerate dehydrogenase(Homo sapiens (Human))
Boehringer Ingelheim Rcv
Curated by ChEMBL
Boehringer Ingelheim Rcv
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of N-terminal His6-tagged human PHGDH (4 to 315 residues) assessed as effect on NADH fluorescence incubated for 2 hrs using 3-PG substrate...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair